Morgan Stanley reiterated their overweight rating on shares of Biohaven Pharmaceutical Holding Co Ltd (NASDAQ:BHVN) in a research report sent to investors on Tuesday morning. The brokerage currently has a $38.00 target price on the stock, down from their previous target price of $47.00.

Several other research analysts have also recently weighed in on the stock. Needham & Company LLC lowered their price target on shares of Biohaven Pharmaceutical Holding Co from $43.00 to $36.00 and set a buy rating on the stock in a research report on Tuesday. BidaskClub lowered shares of Biohaven Pharmaceutical Holding Co from a strong-buy rating to a buy rating in a report on Wednesday, September 20th. Piper Jaffray Companies restated a buy rating and set a $54.00 price objective on shares of Biohaven Pharmaceutical Holding Co in a research report on Tuesday, September 12th. Finally, Zacks Investment Research upgraded shares of Biohaven Pharmaceutical Holding Co from a sell rating to a hold rating in a research report on Friday, September 8th. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of Buy and an average price target of $40.80.

Biohaven Pharmaceutical Holding Co (BHVN) traded down 1.63% on Tuesday, hitting $32.54. The stock had a trading volume of 81,689 shares. Biohaven Pharmaceutical Holding Co has a 12 month low of $17.00 and a 12 month high of $39.51. The stock’s market cap is $1.17 billion. The firm’s 50 day moving average price is $35.38 and its 200-day moving average price is $27.66.

ILLEGAL ACTIVITY WARNING: This story was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this story can be viewed at https://www.watchlistnews.com/biohaven-pharmaceutical-holding-co-ltd-bhvn-receives-overweight-rating-from-morgan-stanley/1608099.html.

About Biohaven Pharmaceutical Holding Co

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.

Analyst Recommendations for Biohaven Pharmaceutical Holding Co (NASDAQ:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Holding Co Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical Holding Co Ltd and related companies with Analyst Ratings Network's FREE daily email newsletter.